Novavax on Thursday tried to calm investors spooked by the delay of full approval of its COVID vaccine shot by U.S.

Novavax is undervalued, presenting an attractive risk-reward profile for long-term investors. Click here to find out why NVAX ...

Novavax Inc. (NASDAQ:NVAX) reported first-quarter 2025 sales of $667 million, compared to $94 million a year ago, beating the ...

WASHINGTON (AP) — Novavax’s closely watched COVID-19 vaccine is on track for full approval after additional discussions with the Food and Drug Administration, the company said Wednesday.

There’s new uncertainty about updated COVID-19 shots this fall after the Trump administration’s handling of a shot from ...

Novavax said on Wednesday U.S. regulators asked the company to produce more data on its COVID-19 vaccine if it gets full ...

Vaccine maker Novavax is seeking to convert the 2022 emergency authorization of its Covid-19 vaccine into full approval. Yet ...

An FDA committee will soon make recommendations about this fall’s Covid-19 vaccines while Novavax still awaits full FDA ...

Novavax said on Thursday discussions with the U.S. health regulator on its COVID-19 shot are ongoing and a pathway to ...

Dr. Marty Makary, chief of the FDA, has expressed doubts about the agency approving the COVID-19 vaccine for winter, stating ...

Novavax swung to profit in the first quarter, helped by reduced costs tied to the development and sale of its COVID-19 vaccine, its only product on the market. The Maryland-based biotech has been ...

Also Read: Trump-Era FDA Appointees Request New Trials For Novavax COVID Vaccine, Reportedly Delaying Approval Timeline The COVID-19 vaccine maker reported an earnings per share of $2.93 ...